2024 has proven to be another year of excellent progress both financially and operationally. Cresemba delivered another strong financial performance, generating royalty revenue approaching CHF100m representing 22.5% growth. With costs carefully controlled, FY’24 represented another profitable year.

18 Feb 2025
Basilea - FY 2024 results

Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Basilea - FY 2024 results
Basilea Pharmaceutica AG (BSLN:SWX) | 0 0 0.0%
- Published:
18 Feb 2025 -
Author:
Brian White | Andrew Keith -
Pages:
4 -
2024 has proven to be another year of excellent progress both financially and operationally. Cresemba delivered another strong financial performance, generating royalty revenue approaching CHF100m representing 22.5% growth. With costs carefully controlled, FY’24 represented another profitable year.